Logo

uniQure Reports First Patient Dosing of AMT-130 in P-Ib/II Trial for the Treatment of Huntington’s Disease

Share this
uniQure Reports First Patient Dosing of AMT-130 in P-Ib/II Trial for the Treatment of Huntington’s Disease

uniQure Reports First Patient Dosing of AMT-130 in P-Ib/II Trial for the Treatment of Huntington’s Disease

Shots:

  • The first two patients have been enrolled in EU P-IIb/II clinical trial to evaluate the safety, PoC, and dosing of AMT-130 in patients with Huntington’s disease at multiple sites in Poland, UK & Germany
  • The patient enrollment is expected to be complete at the end of 2022. Additionally, the company provides the safety and target-engagement data from 10 patient, low-dose cohort in the US trial in Q2’22
  • The study consists of an initial 6mos. post-treatment study period based on long-term follow-up for 5yrs. The study is currently open for recruitment at IPiN and surgery at INC in Poland and is expected to expand in the UK & Germany

Ref: Globe Newswire | Image: The Street

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions